ITGR Stock Analysis: Integer Holdings | NYSE
Medical Devices | NYSE, USA | Market Cap: 3.095m USD | 12M Return: -23.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 39.6M
EPS Trend: 98.4%
Qual. Beats: 0
Rev. Trend: 99.4%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Integer Holdings Corporation (ITGR) is a medical device contract development and manufacturing organization (CDMO) headquartered in Plano, Texas, with operations spanning the United States, Costa Rica, Puerto Rico, Ireland, and other international locations. Founded in 1970 (formerly known as Greatbatch, Inc. before rebranding in July 2016), the company manufactures components and finished devices across a broad range of therapeutic areas, including interventional cardiology, structural heart, peripheral vascular, neurovascular, electrophysiology, oncology, dialysis, and surgical applications.
Its product portfolio spans cardiac rhythm management devices (pacemakers, ICDs, leads), neuromodulation products, rechargeable and non-rechargeable batteries, machined components, enclosures, and portable medical equipment such as ventilators and patient monitors. The company sells primarily to multi-national original equipment manufacturers (OEMs) and operates under the Greatbatch Medical and Lake Region Medical brands. As a CDMO, Integer operates within the outsourced medical device manufacturing segment of the Health Care Equipment sub-industry, a business model where OEMs rely on specialized partners for design, component production, and assembly of regulated medical devices.
- Cardiac rhythm management revenue concentration from top OEM customers
- Margin expansion from facility consolidation and operational efficiency initiatives
- Acquisition strategy targets high-growth neuromodulation and electrophysiology markets
| Net Income: 141.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.46 > 1.0 |
| NWC/Revenue: 30.73% < 20% (prev 28.41%; Δ 2.31% < -1%) |
| CFO/TA 0.06 > 3% & CFO 189.6m > Net Income 141.8m |
| Net Debt (1.50b) to EBITDA (332.6m): 4.52 < 3 |
| Current Ratio: 3.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (34.4m) vs 12m ago 1.52% < -2% |
| Gross Margin: 23.31% > 18% (prev 26.24%; Δ -2.93% > 0.5%) |
| Asset Turnover: 55.14% > 50% (prev 52.91%; Δ 2.23% > 0%) |
| Interest Coverage Ratio: 5.18 > 6 (EBIT TTM 196.7m / Interest Expense TTM 38.0m) |
| A: 0.17 (Total Current Assets 774.8m - Total Current Liabilities 206.3m) / Total Assets 3.41b |
| B: 0.30 (Retained Earnings 1.01b / Total Assets 3.41b) |
| C: 0.06 (EBIT TTM 196.7m / Avg Total Assets 3.35b) |
| D: 0.99 (Book Value of Equity 1.70b / Total Liabilities 1.71b) |
| Altman-Z'' = 3.49 = A |
| DSRI: 0.82 (Receivables 327.8m/379.2m, Revenue 1.85b/1.74b) |
| GMI: 1.13 (GM 26.24% / 23.31%) |
| AQI: 0.96 (AQ_t 0.57 / AQ_t-1 0.60) |
| SGI: 1.06 (Revenue 1.85b / 1.74b) |
| TATA: -0.01 (NI 141.8m - CFO 189.6m) / TA 3.41b) |
| Beneish M = -3.04 (Cap -4..+1) = AA |
As of July 11, 2026, the stock is trading at USD 93.68 with a total of 198,788 shares traded. Over the past week, the price has changed by -1.53%, over one month by +2.53%, over three months by +10.07% and over the past year by -23.07%.
Current recommended Stop Loss: 86.70 (which is 7.5% or 2.6 ATR below the current price).
Integer Holdings has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy ITGR.
- StrongBuy: 7
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 97.6 | 4.1% |
P/E Trailing = 22.6179
P/E Forward = 20.3666
P/S = 1.6677
P/B = 1.9038
P/EG = 2.5466
Revenue TTM = 1.85b USD
EBIT TTM = 196.7m USD
EBITDA TTM = 332.6m USD
Long Term Debt = 1.25b USD (from longTermDebt, last quarter)
Short Term Debt = 8.11m USD (from shortTermDebt, last quarter)
Debt = 1.51b USD (from shortLongTermDebtTotal, last quarter) + Leases 129.9m
Net Debt = 1.50b USD (calculated: Debt 1.51b - CCE 8.12m)
Enterprise Value = 4.60b USD (3.09b + Debt 1.51b - CCE 8.12m)
Interest Coverage Ratio = 5.18 (Ebit TTM 196.7m / Interest Expense TTM 38.0m)
EV/FCF = 46.08x (Enterprise Value 4.60b / FCF TTM 99.8m)
FCF Yield = 2.17% (FCF TTM 99.8m / Enterprise Value 4.60b)
FCF Margin = 5.39% (FCF TTM 99.8m / Revenue TTM 1.85b)
Net Margin = 7.67% (Net Income TTM 141.8m / Revenue TTM 1.85b)
Gross Margin = 23.31% ((Revenue TTM 1.85b - Cost of Revenue TTM 1.42b) / Revenue TTM)
Gross Margin QoQ = 24.93% (prev 22.53%)
Tobins Q-Ratio = 1.35 (Enterprise Value 4.60b / Total Assets 3.41b)
Interest Expense / Debt = 2.51% (Interest Expense 38.0m / Debt 1.51b)
Taxrate = 10.67% (16.9m / 158.7m)
NOPAT = 175.7m (EBIT 196.7m * (1 - 10.67%))
Current Ratio = 3.75 (Total Current Assets 774.8m / Total Current Liabilities 206.3m)
Debt / Equity = 0.89 (Debt 1.51b / totalStockholderEquity, last quarter 1.70b)
Debt / EBITDA = 4.52 (Net Debt 1.50b / EBITDA 332.6m)
Debt / FCF = 15.06 (Net Debt 1.50b / FCF TTM 99.8m)
Total Stockholder Equity = 1.72b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.23% (Net Income 141.8m / Total Assets 3.41b)
RoE = 8.23% (Net Income TTM 141.8m / Total Stockholder Equity 1.72b)
RoCE = 6.61% (EBIT 196.7m / Capital Employed (Equity 1.72b + L.T.Debt 1.25b))
RoIC = 5.48% (NOPAT 175.7m / Invested Capital 3.21b)
WACC = 5.78% (E(3.09b)/V(4.61b) * Re(7.51%) + D(1.51b)/V(4.61b) * Rd(2.51%) * (1-Tc(0.11)))
Discount Rate = 7.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 2.22 | Cagr: 0.58%
[DCF] Terminal Value 73.88% ; FCFF base≈104.5m ; Y1≈95.7m ; Y5≈84.2m
[DCF] Fair Price = N/A (negative equity: EV 1.34b - Net Debt 1.50b = -165.5m; debt exceeds intrinsic value)
EPS Correlation: 98.42 | EPS CAGR: 16.65% | SUE: 0.22 | # QB: 0
Revenue Correlation: 99.38 | Revenue CAGR: 8.29% | SUE: 2.01 | # QB: 1
EPS current Quarter (2026-06-30): EPS=1.38 | Chg30d=-10.30% | Revisions=-73% | Analysts=8
EPS next Quarter (2026-09-30): EPS=1.69 | Chg30d=-8.15% | Revisions=-73% | Analysts=8
EPS current Year (2026-12-31): EPS=6.08 | Chg30d=-6.29% | Revisions=-75% | GrowthEPS=-5.0% | GrowthRev=-2.0%
EPS next Year (2027-12-31): EPS=6.81 | Chg30d=-5.78% | Revisions=-73% | GrowthEPS=+11.9% | GrowthRev=+5.9%
[Analyst] Revisions Ratio: -92% (up=0, down=33)